Our expert physicians are involved in ground-breaking research across a range of specialties

hero banner


Recurrent Prostate Cancer

Authors: Lenzo Nat, BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD , Lim Tee, MBBS, FRANCR , Sohi J.S

Journal: Appl Radiol, volume: Jul/Aug, pages 40-43

Year: 2021


Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments

Authors: Andrea Farolfi; Wolfgang Fendler; Amir Iravani; Uwe Haberkorn; Rodney Hicks; Ken Herrmann; Jochen Walz; Stefano Fanti

Journal: Eur Urol Oncol, volume: Mar;2(2), pages 152-162

Year: 2019


Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer

Authors: Heck M; Tauber R; Schwaiger S et al.;

Year: 2018


[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Authors: Michael S Hofman; John Violet; Rodney J Hicks; Justin Ferdinandus; Sue Ping Thang; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Declan G Murphy; Peter Eu; Price Jackson; Mark Scalzo; Scott G Williams; Shahneen Sandhu

Journal: The Lancet Oncology, volume: Jun; 19(6), pages 825-833

Year: 2018


Current status of theranostics in prostate cancer

Authors: Virgolini I; Decristoforo C; Haug A et al.

Journal: Current status of theranostics in prostate cancer

Year: 2017